Spatial structure of β-cyclodextrin clathrates with 1,4-benzodiazepine derivatives

Abstract

Understanding the mechanisms of mutual recognition and complementary binding of molecules in guest-The boom development of cyclodextrin (CD) chemistry is explained by the unique ability of these compounds to form guest-host complexes with many organic and inorganic molecules [1], which belong to virtual-topological isomers, and is related with the evolution of a new field of chemistry -supramolecular chemistry [2]. This ability makes it possible to use CD as enzyme models or, in general, as molecular sensors modeling receptor binding [3, 4], as catalysts for chemical reactions [5], modifiers for pharmaceuticals [6][7][8], etc.A rather promising technique for raising the solubility and biological accessibility of drugs is synthesis of their inclusion complexes with cyclodextrins or their derivatives. In these complexes, volatile and liquid substances are available in the solid phase, their odor and taste may be modified, and incompatible drugs may be combined within one drug form [6]. These possibilities are realized best if the host molecule is a cavitand. Cyclodextrius are just cavitands. For example, the fl-CD molecule (cyclic heptamer of glucose) has the form of a truncated cone (bracelet), which is A. V. Bogatskii Physicochemical Institute, Ukrainian National Academy of Sciences.

Bioaccessibility of cinazepam introduced as inclusion complex with β-cyclodextrin

“…Inclusion complexes of biologically active substances with cyclodextrins are used for modeling the ligand-receptor interactions and for increasing the stability, solubility, and bioaccessibility of drugs [2,3]. Previously we have synthesized the inclusion complexes of cinazepam with [3-cyclodexwin (13-CD) and studied their structure in solution and in the solid state [2,4].…”

Bioactive Substances: Nanoencapsulation

“…poorly water-soluble drugs. [102] Both types of prodrugs provide brain targeting followed by the sustained release. Among them heptakis(2,6-di-Oethyl)-, heptakis(2,3,6-tri-O-ethyl)-, and heptakis(2,3,6-tri-O-butanoyl)-β-cyclodextrin were the first slow-release carriers to be used in conjunction with diltiazem, isosorbide dinitrate, and salbutamol.…”